The Australian Therapeutic Goods Administration added AOD-9604 to its Poisons Standard under performance and image-enhancing drugs (PIEDs), and possession without a legal prescription is restricted in Australia
This is a metabolic process which has many actions in the body but helps to produce energy
Food and Drug Administration (FDA) in 2021 for chronic weight management in adults and children 12 and older with obesity (BMI of 30 or more) and for adults who are overweight (BMI of 27 or more) with one or more weight-related health conditions, such as type 2 diabetes or high blood pressure
However, for those who want to maintain normal eating patterns, avoid central appetite manipulation, or who cannot tolerate the gastrointestinal effects common with GLP-1 drugs, AOD-9604 offers an alternative mechanism
In the UK, the MHRA has approved semaglutide (Wegovy) and liraglutide (Saxenda) specifically for weight management in adults with obesity or overweight with weight-related comorbidities (as per NICE TA875 and TA664)
